• Mashup Score: 0

    Patients with diabetes and recent MI had reduced risk for first and total CV events with colchicine compared with placebo, according to new data from the COLCOT trial. As Healio previously reported, in the main results of COLCOT, adults with a recent MI assigned colchicine, an anti-inflammatory medication used to treat gout, had 23% reduced risk for first CV events and 34% reduced risk for

    Tweet Tweets with this article
    • “Colchicine at 0.5 mg per day significantly reduces the risk of first and total [CV] events by 35% and 47%, respectively, in patients with diabetes and a recent [MI],” #AHA20 @AHAMeetings @HeartNews @American_Heart #cardiotwitter @EndocrineToday https://t.co/SHiJ5hfcud

  • Mashup Score: 16

    Patients with diabetes and recent MI had reduced risk for first and total CV events with colchicine compared with placebo, according to new data from the COLCOT trial. As Healio previously reported, in the main results of COLCOT, adults with a recent MI assigned colchicine, an anti-inflammatory medication used to treat gout, had 23% reduced risk for first CV events and 34% reduced risk for

    Tweet Tweets with this article
    • Patients with diabetes and recent MI had reduced risk for first and total CV events with #colchicine compared with placebo, according to new data from the COLCOT trial #AHA20 @AHAMeetings @heartnews @american_heart #cardiotwitter @EndocrineToday https://t.co/SHiJ5hfcud

  • Mashup Score: 1

    In a national private health care database, age, male sex and comorbidities increased risk for death in patients hospitalized with COVID-19, according to data presented at the virtual American Heart Association Scientific Sessions. The findings were mostly consistent with data from the AHA’s COVID-19 CVD registry, also presented at the meeting.

    Tweet Tweets with this article
    • ICYMI: “It is a little bit challenging... to understand which are really driving the risk vs. which are just more statistically significant in the model,” #AHA20 #cardiotwitter @AnnMarieNavar @HealioPulm @EndocrineToday @InfectDisNews https://t.co/uMNUVZstsR

  • Mashup Score: 1

    In a national private health care database, age, male sex and comorbidities increased risk for death in patients hospitalized with COVID-19, according to data presented at the virtual American Heart Association Scientific Sessions. The findings were mostly consistent with data from the AHA’s COVID-19 CVD registry, also presented at the meeting.

    Tweet Tweets with this article
    • ICYMI: “It is a little bit challenging... to understand which are really driving the risk vs. which are just more statistically significant in the model,” #AHA20 #cardiotwitter @AnnMarieNavar @HealioPulm @EndocrineToday @InfectDisNews https://t.co/uMNUVZstsR

  • Mashup Score: 4

    In a national private health care database, age, male sex and comorbidities increased risk for death in patients hospitalized with COVID-19, according to data presented at the virtual American Heart Association Scientific Sessions. The findings were mostly consistent with data from the AHA’s COVID-19 CVD registry, also presented at the meeting.

    Tweet Tweets with this article
    • In a national private health care database, age, male sex and comorbidities increased risk for death in patients hospitalized with #COVID_19 #AHA20 @AHAMeetings @heartnews #cardiotwitter @AnnMarieNavar @UTSWNews @UTSWNews @HealioPulm @EndocrineToday https://t.co/uMNUVZstsR